美国 - 英文 - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - fayosim™ is indicated for use by females of reproductive age to prevent pregnancy. do not prescribe fayosim to women who are known to have the following conditions: • a high risk of arterial or venous thrombotic diseases. examples include women who are known to: - smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)]. - have deep vein thrombosis or pulmonary embolism, now or in the past [ see warnings and precautions (5.1)]. - have cerebrovascular disease [see warnings and precautions (5.1)]. - have coronary artery disease [see warnings and precautions (5.1)]. - have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1)]. - have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)]. - have uncontrolled hypertension [see warnings and precautions (5.3)]. - have

美国 - 英文 - NLM (National Library of Medicine)

northstar rx llc - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.05 mg - oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization and the iud, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. *depending on method (calendar, ovulation, symptothermal, post-ovulation) adapted from hatcher ra et al, contraceptive technology : 17t h revised edition . ny, ny: ardent media, inc., 1998 levonest™ is contraindicated in females who are known to have or develop the following conditions: thrombophlebitis or thromboembolic disorders. a past history of deep-vein-thrombophlebitis or thromboembolic disorders. cerebral-vascular or coronary-artery disease. current diagnosis or history of breast cancer

美国 - 英文 - NLM (National Library of Medicine)

mayne pharma inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.05 mg - oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization and the iud, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. oral contraceptives should not be used in women with any of the following conditions: thrombophlebitis or thromboembolic disorders. a past history of deep-vein thrombophlebitis or thromboembolic disorders. cerebral-vascular or coronary-artery disease. current diagnosis of, or history of, breast cancer, which may be hormone sensitive. carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia. undiagnosed abnormal genital bleeding. cholestatic jaundice of pregnancy or jaundic

美国 - 英文 - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - jolessa® is indicated for use by females of reproductive potential to prevent pregnancy. jolessa is contraindicated in females who are known to have or develop the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include females who are known to: - smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)]. - have current or history of deep vein thrombosis or pulmonary embolism [see warnings and precautions (5.1 )]. - have cerebrovascular disease [see warnings and precautions (5.1 )]. - have coronary artery disease [see warnings and precautions (5.1 )]. - have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1 )]. - have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1 )]. - have uncontrolled hypertension or hypertension with vascular disease [see warnings and precautions (5.4)]. - h

美国 - 英文 - NLM (National Library of Medicine)

northstar rx llc - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - setlakin is indicated for use by females of reproductive potential to prevent pregnancy. setlakin is contraindicated in females who are known to have or develop the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include females who are known to: - smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)]. - have current or history of deep vein thrombosis or pulmonary embolism [see warnings and precautions (5.1 )]. - have cerebrovascular disease [see warnings and precautions (5.1 )]. - have coronary artery disease [see warnings and precautions (5.1 )]. - have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1 )]. - have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1 )]. - have uncontrolled hypertension or hypertension with vascular disease [see warnings and precautions (5.4)]. - h

美国 - 英文 - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.1 mg - oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table iii lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. % of women experiencing an accidental pregnancy within the first year of use % of women continuing use at one year3 method (1) typical use1  (2) perfect use2  (3) (4) chance4 85 85 spermicides5 26 6 40 periodic abstinence 25 63 calendar 9 ovulation method 3 sympto-thermal6 2 post ovulation 1 withdrawal 19 4 cap7 parous women 40 26 42 nulliparous women 20 9 56 sponge parous women 40 20 42 nulliparous women 20 9 56 diaphragm7 20 6 5

美国 - 英文 - NLM (National Library of Medicine)

mayne pharma inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.1 mg - oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table iii lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. levonorgestrel and ethinyl estradiol tablets are contraindicated in females who are known to have or develop the following conditions: - thrombophlebitis or thromboembolic disorders - a past history of deep-vein thrombophlebitis or thromboembolic disorders - cerebral-vascular or coronary-artery disease - current diagnosis of, or history of, breast cancer, which may be hormone sensitive - carcinoma of the endometrium or other known or suspected estrogen dependent neoplasia - undiagnosed abnormal genital bleeding

美国 - 英文 - NLM (National Library of Medicine)

physicians total care, inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.05 mg - oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table ii lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization and the iud, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. combination oral contraceptives should not be used in women with any of the following conditions: thrombophlebitis or thromboembolic disorders. a past history of deep-vein thrombophlebitis or thromboembolic disorders. cerebral-vascular or coronary-artery disease. thrombogenic valvulopathies. thrombogenic rhythm disorders. diabetes with vascular involvement. uncontrolled hypertension. known or suspected carcinoma of the breast. carcinoma of the endometrium or other known or suspected estrogen-dependen

美国 - 英文 - NLM (National Library of Medicine)

physicians total care, inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.1 mg - oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.  oral contraceptives are highly effective. table ii lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and norplant® system, depends upon the reliability with which they are used.  correct and consistent use of methods can result in lower failure rates. in a clinical trial with lutera, 1,477 subjects had 7,720 cycles of use and a total of 5 pregnancies were reported. this represents an overall pregnancy rate of 0.84 per 100 woman-years. this rate includes patients who did not take the drug correctly. one or more pills were missed during 1,479 (18.8%) of the 7,870 cycles; thus all tablets were taken during 6,391 (81.2%) of the 7,870 cycles. of the total 7,870 cycles, a total of 150 cycles were excluded from the calculation of the

美国 - 英文 - NLM (National Library of Medicine)

physicians total care, inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.050 mg - oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization and the iud, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. oral contraceptives should not be used in women with any of the following conditions: - thrombophlebitis or thromboembolic disorders. - a past history of deep-vein thrombophlebitis or thromboembolic disorders. - cerebral-vascular or coronary-artery disease. - known or suspected carcinoma of the breast. - carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia. - undiagnosed abnormal genital bleeding. - cholestatic jaundice of pregnancy or jaundice with prior pill use. - h